News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

News

Article

August 29, 2023

AstraZeneca Joins Legal Battle Against IRA

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

USA flag, dollars and inscription inflation reduction act. Image Credit: Adobe Stock Images/Vitalii Vodolazskyi

Image Credit: Adobe Stock Images/Vitalii Vodolazskyi

Claiming the Inflation Reduction Act’s (IRA) drug provisions to be unconstitutional, AstraZeneca has become the latest drugmaker to pursue legal action against the US government. As reported by BioPharma Dive, the drugmaker’s lawsuit claims Medicare is unlawfully implementing provisions of last year’s Inflation Reduction Act, which provides the agency with authority to negotiate prices of certain top-selling drugs.

Currently, drugmakers that refuse to cooperate with Medicare on a lower price are subject to a heavy tax that’s only avoidable if products are removed from the insurance program.

“The IRA forces manufacturers to engage in purported ‘negotiations’ but affords them no bargaining power, no meaningful opportunity to walk away, and no ability to protect their interests against a so-called ‘maximum fair price’ capped at an amount drastically below actual fair market value,” alleged the British drug manufacturer in its lawsuit.

Reference: AstraZeneca the latest pharma to challenge drug pricing law. BioPharma Dive. August 25, 2023. Accessed August 29, 2023. https://www.biopharmadive.com/news/astrazeneca-ira-lawsuit-drug-pricing/691869/

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Related Content
Advertisement
Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma
August 4th 2025

Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma

Michael Christel
Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.
Asembia 2025: Understanding the Inflation Reduction Act
August 4th 2025

Asembia 2025: Understanding the Inflation Reduction Act

Nicholas Saraceno, Editor
A seminar shares key observations and learnings from the first round of direct price negotiations.
Asembia 2025: A General Landscape of the Pharmaceutical Industry
August 4th 2025

Asembia 2025: A General Landscape of the Pharmaceutical Industry

Nicholas Saraceno, Editor
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
A Rocky Road for Regulation
August 4th 2025

A Rocky Road for Regulation

Mike Hollan
With the Inflation Reduction Act now in flux, how will the government and industry respond?
Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications
August 4th 2025

Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications

Don Tracy, Associate Editor
The proposal aims to reduce out-of-pocket costs for a number of anti-obesity medications by 95%.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
August 4th 2025

MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?

Don Tracy, Associate Editor
Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
Related Content
Advertisement
Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma
August 4th 2025

Orders of Magnitude: Gauging Future Pricing-and-Policy Reverberations in Pharma

Michael Christel
Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.
Asembia 2025: Understanding the Inflation Reduction Act
August 4th 2025

Asembia 2025: Understanding the Inflation Reduction Act

Nicholas Saraceno, Editor
A seminar shares key observations and learnings from the first round of direct price negotiations.
Asembia 2025: A General Landscape of the Pharmaceutical Industry
August 4th 2025

Asembia 2025: A General Landscape of the Pharmaceutical Industry

Nicholas Saraceno, Editor
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
A Rocky Road for Regulation
August 4th 2025

A Rocky Road for Regulation

Mike Hollan
With the Inflation Reduction Act now in flux, how will the government and industry respond?
Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications
August 4th 2025

Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications

Don Tracy, Associate Editor
The proposal aims to reduce out-of-pocket costs for a number of anti-obesity medications by 95%.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
August 4th 2025

MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?

Don Tracy, Associate Editor
Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.